预防人工关节置换术后下肢深静脉血栓形成的护理对策

目的:探讨预防关节置换术后下肢深静脉血栓形成的有效护理对策.方法:针对下肢深静脉血栓形成的高危因素,对行人工关节置换的患者行预防性药物,物理预防以及系统性功能锻炼.结果:181例术后患者中有41例发生静脉血栓,发生率为22.2%.治疗后均痊愈出院.结论:细致的护理和有效的措施是预防下肢静脉血栓的关键,积极的治疗和护理可避免深静脉血栓的形成后的严重的并发症.     

美国CDC《2021年性传播感染诊治指南》外阴阴道假丝酵母菌病诊治解读

美国疾病控制和预防中心(CDC)发布了最新版的《2021年性传播感染诊治指南》(Sexually Transmitted Infection Treatment Guidelines,2021),其中外阴阴道假丝酵母菌病(VVC)部分有一些新的修订。本文对该部分进行解读,并与2015年美国CDC指南进行比较分析,以期为临床医生对VVC的规范诊治和国内新版指南的修订提供参考。该指南主要更新为复发性VVC(RVVC)的诊断由一年内有症状的VVC发作4次或以上更改为一年内发作3次或以上。指南目前不推荐使用益生菌制剂治疗单纯性VVC。此外,对于非白假丝酵母菌感染患者,推荐600 mg硼酸胶囊阴道给药,每日1次,持续治疗时间由2015年版的2周延长为3周。     

人工关节置换术对老年股骨粗隆间骨折患者Harris评分和预后的影响

目的:进一步探讨人工关节置换术对老年股骨粗隆间骨折Harris评分和预后的临床影响,为临床实践提供借鉴和参考依据。方法:选取我院骨科近三年临床收治的老年股骨粗隆间骨折患者226例,按照患者手术方式将其分成研究组和对照组,每组113例。分别给予患者内固定术和人工关节置换术治疗,对两组患者前术后疼痛评分、术后6个月和12个月的Harris评分以及术后并发症发生情况进行观察和比较。结果:(1)术前两组患者疼痛评分差异不大,且无统计学意义;术后3周和3个月的疼痛评分组间比较,研究组均低于对照组,且差异有统计学意义;(2)研究组术后6个月和12个月的Harris评分结果的优良率水平显著高于对照组,且差异有统计学意义;(3)研究组患者并发症发生率显著低于对照组。结论:人工关节置换术能够显著改善老年股骨粗隆间骨折Harris评分提高患者临床预后,是临床治疗老年股骨粗隆间骨折的理想手术方式之一。     

导管接触溶栓与机械辅助吸栓治疗急性髂股静脉血栓的对比研究

目的:评价导管接触溶栓与机械辅助吸栓治疗急性髂股静脉血栓的临床效果。方法:回顾性分析162例急性下肢深静脉血栓(髂股静脉血栓)形成患者临床资料,其中导管溶栓治疗组(A组)80例、机械辅助吸栓组(B组)82例,比较两组患者治疗后患肢深静脉溶栓率、消肿率、并发症发生率、治疗时间的差异。结果:急性下肢髂股静脉血栓溶栓率B组(46.45±11.56)%显著高于A组(32.05±10.7)%(P0.05)。患肢消肿率B组(68.68±10.75)%和A组(41.34±11.26)%有明显统计学差异(P0.05)。两组并发症发生率无明显统计学意义。两组溶栓时间A组明显长于B组,两组间比较有明显统计学差异。结论:机械辅助吸栓治疗急性髂股静脉血栓早期疗效好于导管接触溶栓。     

关节置换术后抗凝药物预防深静脉血栓及相关并发症的临床研究进展

抗凝药物有助于预防全髋关节置换术和全膝关节置换术后深静脉血栓形成,临床上最常使用的传统抗凝药物如低分子肝素、华法林等可以起到很好的预防效果。目前有一类新的口服抗凝药物已经用于临床,为关节置换术后患者带来了一种更方便、安全和有效预防血栓的治疗选择。本篇综述主要针对传统抗凝药物低分子肝素及维生素K拮抗剂,直接凝血酶抑制剂达比加群,以及选择性Xa因子抑制剂利伐沙班和阿哌沙班,对迄今为止传统抗凝药物在全髋关节置换术和全膝关节置换术患者中的临床使用经验、优缺点、以及新型口服抗凝药物最新临床用药进展进行综述,为关节置换术后患者预防深静脉血栓提供用药参考。     

中药防治假体周围骨溶解的研究进展

现如今人工关节置换术越来越多的应用于重建关节功能改善关节疾病患者的生活质量,但是术后并发症严重影响了手术的效果,人工假体周围骨溶解及假体无菌性松动又是人工关节置换术后失败的主要原因之一,所以如何预防以及发病后如何去治疗成为现今关节医生面临的重要课题。OPG/RANKL/RANK系统,炎性因子的产生,破骨细胞、成骨细胞这些都是影响人工假体术后产生无菌性松动,和引发假体周围骨溶解的重要因素,有效药物的干预治疗成为现如今关节置换术后以及围手术期的热门话题,中药因其副作用小,疗效独特,及深入的研究逐渐受到广大医生的注意,因此中药在治疗人工假体松动及骨溶解方面也得到了重大突破,本文从中医肾藏精,精生髓,髓能养骨理论着手总结中药作用于OPG/RANKL/RANK系统,抑制炎性因子、破骨细胞及促进成骨细胞增殖的研究现状。     

人工关节置换与加压螺钉内固定治疗高龄骨质疏松性股骨颈骨折的疗效观察

目的:探讨人工关节置换与加压螺钉内固定治疗高龄骨质疏松性股骨颈骨折的疗效。方法:选取2010年8月至2013年3月我院收治的120例高龄骨质疏松性股骨颈骨折患者,将所有患者随机分为人工置换组和内固定组两组,每组各60例,内固定组采用加压螺钉内固定术治疗,人工置换组采取人工关节置换术治疗,评定两组患者的手术时间、术中出血量、下地时间、术后并发症发生率及末次随访时Harris评分优良率。结果:人工置换组手术时间及术中出血量分别为(124.8±16.7)min、(369.2±99.7)ml,明显高于内固定组的(73.5±15.1)min、(78.4±25.6)ml;但人工置换组术后下地时间为(15.3±4.8)d,明显低于内固定组的(40.2±7.5)d;人工置换组与内固定组患者术后并发症的发生率分别为20%、66.7%,人工置换组明显低于内固定组,其中,泌尿系褥疮的组间差异最为显著;末次随访时Harris评分优良率,相比于内固定组的61.67%,人工置换组为78.33%,明显偏高。差异有统计学意义(P0.05)。结论:加压螺钉内固定术和人工关节置换术在治疗高龄骨质疏松性股骨颈骨折方面各有优劣,对于能够耐受人工关节置手术且经济条件好的的老年患者而言,采用人工关节置换术治疗,疗效更佳。     

创伤骨科中应用人工关节治疗技术的效果观察

目的:探讨创伤骨科中应用人工关节治疗技术的效果。方法:选取2012年12月-2014年5月收治于本院的45例老年股骨颈骨折患者作为研究对象,收集患者的临床资料并对其进行回顾性分析,32例应用人工股骨头置换术进行治疗,13例予以全髋关节置换术进行治疗,对患者情况采用Harris髋关节评分标准进行评估,观察总结其治疗方法和疗效。结果:经治疗,45例患者全部安全度过围术期,1例出现轻度尿路感染,无假体松动与脱位发生,Harris髋关节评分为(88.67±4.85)分,优良率为95.6%。结论:创伤骨科中应用人工关节治疗技术治疗股骨颈骨折疗效显著,具有较高的安全性,可在临床上进行推广应用。     

来那度胺致多发性骨髓瘤患者静脉血栓形成的机制

来那度胺是一种新型的免疫调节药物,已被广泛应用于治疗多发性骨髓瘤,但其所致静脉血栓形成的副作用也越来越明显。当单独使用来那度胺治疗多发性骨髓瘤时,患者静脉血栓的发生率比较低,而其与地塞米松、化疗药物等联合使用治疗多发性骨髓瘤时,静脉血栓的发生率明显高于单独使用。来那度胺致多发性骨髓瘤患者静脉血栓形成的机制目前尚未完全阐明,国内外研究显示,其主要与内皮细胞功能紊乱、组织因子与磷脂酰丝氨酸暴露增加及体内的高凝状态相关。本文主要就来那度胺致多发性骨髓瘤患者静脉血栓形成的机制进行了简要综述。     

PICC置管后致静脉血栓的护理

目的总结分析经外周静脉置入中心静脉导管(PICC)后并发静脉血栓的情况、治疗方法及转归,并制定针对性的护理干预措施。方法选择我院放疗科一病区2012年1月~2015年6月收治的150例鼻咽癌患者为研究对象,患者均因治疗需要行PICC置管,并在循证基础上给予针对性护理干预。结果 9例患者置管后发生静脉血栓,发生率为6.00%;溶栓治疗后9例患者症状均明显缓解,无栓子脱落导致脑栓塞和肺栓塞病例。结论做好PICC置管后上肢静脉血栓的预防性护理和上肢静脉血栓形成后的护理,杜绝或减少静脉血栓的发生原因,从而降低静脉血栓的发生率。同时及早发现上肢静脉血栓形成,并及时采取恰当的处理措施,可减轻患者的痛苦及经济负担,延长PICC留置时间。     

A Survey of the Knowledge of Venous Thromboembolism Prophylaxis among the Medical Staff of Intensive Care Units in North China

Background

Guideline concordance for venous thromboembolism (VTE) prophylaxis in critically ill patients in intensive care units (ICUs) varies across different countries.

Objective

To explore how the medical staff of ICUs in China comprehend and practice VTE prophylaxis.

Method

Questionnaires comprising 39 questions and including 4 dimensions of thromboprophylaxis were administered in ICUs in North China.

Results

In all, 52 ICUs at 23 tertiary hospitals in 7 Chinese provinces and municipalities were surveyed. A total of 2500 questionnaires were sent, and 1861 were returned, corresponding to a response rate of approximately 74.4%. Of all surveyed medical staff, 36.5% of physicians and 22.2% of nurses were aware of the guidelines in China, and 19.0% of physicians and 9.5% of nurses comprehended the 9^th edition of the guidelines of the American College of Chest Physicians (ACCP). Additionally, 37.6% of the medical staff chose a prophylaxis method based on the related guidelines, and 10.3% could demonstrate the exact indication for mechanical pattern application. Worries about skin injury, difficulty with removal and discomfort during mechanical thromboprophylaxis were cited by more than 30% of nurses, which was significantly more frequent than for physicians (graduated compression stockings: 54.3% VS 34.1%, 60.7% VS 49%, and 59.4% VS 54%, p = 0.000; intermittent pneumatic compression: 31% VS 22.2%, 19.2% VS 13.9%, and 37.8% VS 27.2%, p = 0.000).

Conclusions and Relevance

The knowledge of VTE prophylaxis among the medical staff of ICUs in North China remains limited, which may lead to a lack of standardization of VTE prophylaxis. Strengthened, standardized training may help medical staff to improve their comprehension of the relevant guidelines and may finally reduce the occurrence of VTE in ICUs and improve the prognosis of critically ill patients with VTE.     

Surgical Site Infections and Other Postoperative Complications following Prophylactic Anticoagulation in Total Joint Arthroplasty

Background

Anticoagulants reduce the risk of venous thromboembolism (VTE) after total joint replacement. However, concern remains that pharmacologic VTE prophylaxis can lead to bleeding, which may impact on postoperative complications such as infections and reoperations.

Methods and Findings

From the Global Orthopedic Registry (GLORY), we reviewed 3,755 patients in US who elected for primary total hip or knee arthroplasty, received either warfarin or low molecular weight heparin (LMWH) as VTE prophylactics, and had up-to-90-day follow-up after discharge. We compared incidence rates of VTE, infections and other complications between LMWH and warfarin groups, and used multivariate analyses with propensity score weighting to generate the odds ratio (OR). Patients receiving LMWH tended to be older and higher in the American Society of Anesthesiologists grade scores. In contrast, warfarin was used more frequently for hip arthroplasty with longer duration among patients with more pre-existing comorbidity (all P<0.02). A weight variable was created with propensity score to account for differences in covariate distributions. Propensity score-weighted analyses showed no differences in VTE complications. However, compared to warfarin, LMWH was associated with significantly higher rates of bleeding (6.2% vs. 2.1%; OR = 3.82, 95% confidence interval [CI], 2.64 to 5.52), blood transfusion (29.4% vs. 22.0%; OR = 1.75, 95% CI, 1.51 to 2.04), reoperations (2.4% vs. 1.3%; OR = 1.77, 95% CI, 1.07 to 2.93) and infections (1.6% vs. 0.6%; OR = 2.79, 95% CI, 1.42 to 5.45). Similar results were obtained from compliant uses of warfarin (26%) and LMWH (62%) according to clinical guidelines. While surgical site infections were mostly superficial, current study was underpowered to compare incidence rates of deep infections (<1.0%).

Conclusions

Surgical site infections and reoperations in 3 months following primary total joint arthroplasty may be associated with anticoagulant use that exhibited higher bleeding risk. Long-term complications and deep wound infections remain to be studied.     

Impact of Thromboprophylaxis across the US Acute Care Setting

Background

The risk of venous thromboembolism (VTE) can be reduced by appropriate use of anticoagulant prophylaxis. VTE prophylaxis does, however, remain substantially underused, particularly among acutely ill medical inpatients. We sought to evaluate the clinical and economic impact of increasing use of American College of Chest Physicians (ACCP)-recommended VTE prophylaxis among medical inpatients from a US healthcare system perspective.

Methods and Findings

In this retrospective database cost-effectiveness evaluation, a decision-tree model was developed to estimate deaths within 30 days of admission and outcomes attributable to VTE that might have been averted by use of low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). Incremental cost-effectiveness ratio was calculated using “no prophylaxis” as the comparator. Data from the ENDORSE US medical inpatients and the US nationwide Inpatient Sample (NIS) were used to estimate the annual number of eligible inpatients who failed to receive ACCP-recommended VTE prophylaxis. The cost-effectiveness analysis indicated that VTE-prevention strategies would reduce deaths by 0.5% and 0.3%, comparing LMWH and UFH strategies with no prophylaxis, translating into savings of $50,637 and $25,714, respectively, per death averted. The ENDORSE findings indicated that 51.1% of US medical inpatients were at ACCP-defined VTE risk, 47.5% of whom received ACCP-recommended prophylaxis. By extrapolating these findings to the NIS and applying cost-effectives analysis results, the full implementation of ACCP guidelines would reduce number of deaths (by 15,875 if using LMWH or 10,201 if using UFH), and was extrapolated to calculate the cost reduction of $803M for LMWH and $262M for UFH.

Conclusions

Efforts to improve VTE prophylaxis use in acutely ill inpatients are warranted due to the potential for reducing VTE-attributable deaths, with net cost savings to healthcare systems.     

System dynamics to model the unintended consequences of denying payment for venous thromboembolism after total knee arthroplasty

Background

The Hospital Acquired Condition Strategy (HACS) denies payment for venous thromboembolism (VTE) after total knee arthroplasty (TKA). The intention is to reduce complications and associated costs, while improving the quality of care by mandating VTE prophylaxis. We applied a system dynamics model to estimate the impact of HACS on VTE rates, and potential unintended consequences such as increased rates of bleeding and infection and decreased access for patients who might benefit from TKA.

Methods and Findings

The system dynamics model uses a series of patient stocks including the number needing TKA, deemed ineligible, receiving TKA, and harmed due to surgical complication. The flow of patients between stocks is determined by a series of causal elements such as rates of exclusion, surgery and complications. The number of patients harmed due to VTE, bleeding or exclusion were modeled by year by comparing patient stocks that results in scenarios with and without HACS. The percentage of TKA patients experiencing VTE decreased approximately 3-fold with HACS. This decrease in VTE was offset by an increased rate of bleeding and infection. Moreover, results from the model suggest HACS could exclude 1.5% or half a million patients who might benefit from knee replacement through 2020.

Conclusion

System dynamics modeling indicates HACS will have the intended consequence of reducing VTE rates. However, an unintended consequence of the policy might be increased potential harm resulting from over administration of prophylaxis, as well as exclusion of a large population of patients who might benefit from TKA.     

Diet as prophylaxis and treatment for venous thromboembolism?

Background

Both prophylaxis and treatment of venous thromboembolism (VTE: deep venous thrombosis (DVT) and pulmonary emboli (PE)) with anticoagulants are associated with significant risks of major and fatal hemorrhage. Anticoagulation treatment of VTE has been the standard of care in the USA since before 1962 when the U.S. Food and Drug Administration began requiring randomized controlled clinical trials (RCTs) showing efficacy, so efficacy trials were never required for FDA approval. In clinical trials of 'high VTE risk' surgical patients before the 1980s, anticoagulant prophylaxis was clearly beneficial (fatal pulmonary emboli (FPE) without anticoagulants = 0.99%, FPE with anticoagulants = 0.31%). However, observational studies and RCTs of 'high VTE risk' surgical patients from the 1980s until 2010 show that FPE deaths without anticoagulants are about one-fourth the rate that occurs during prophylaxis with anticoagulants (FPE without anticoagulants = 0.023%, FPE while receiving anticoagulant prophylaxis = 0.10%). Additionally, an FPE rate of about 0.012% (35/28,400) in patients receiving prophylactic anticoagulants can be attributed to 'rebound hypercoagulation' in the two months after stopping anticoagulants. Alternatives to anticoagulant prophylaxis should be explored.

Methods and Findings

The literature concerning dietary influences on VTE incidence was reviewed. Hypotheses concerning the etiology of VTE were critiqued in relationship to the rationale for dietary versus anticoagulant approaches to prophylaxis and treatment. Epidemiological evidence suggests that a diet with ample fruits and vegetables and little meat may substantially reduce the risk of VTE; vegetarian, vegan, or Mediterranean diets favorably affect serum markers of hemostasis and inflammation. The valve cusp hypoxia hypothesis of DVT/VTE etiology is consistent with the development of VTE being affected directly or indirectly by diet. However, it is less consistent with the rationale of using anticoagulants as VTE prophylaxis. For both prophylaxis and treatment of VTE, we propose RCTs comparing standard anticoagulation with low VTE risk diets, and we discuss the statistical considerations for an example of such a trial.

Conclusions

Because of (a) the risks of biochemical anticoagulation as anti-VTE prophylaxis or treatment, (b) the lack of placebo-controlled efficacy data supporting anticoagulant treatment of VTE, (c) dramatically reduced hospital-acquired FPE incidence in surgical patients without anticoagulant prophylaxis from 1980 - 2010 relative to the 1960s and 1970s, and (d) evidence that VTE incidence and outcomes may be influenced by diet, randomized controlled non-inferiority clinical trials are proposed to compare standard anticoagulant treatment with potentially low VTE risk diets. We call upon the U. S. National Institutes of Health and the U.K. National Institute for Health and Clinical Excellence to design and fund those trials.     

Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?

Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA) in non-cancer patients with venous thromboembolism (VTE), and long-term therapy with low-molecular weight heparin (LMWH) for those with cancer. We used data from RIETE (international registry of patients with VTE) to report the use of long-term anticoagulant therapy over time and to identify predictors of anticoagulant choice (regarding international guidelines) in patients with- and without cancer. Among 35,280 patients without cancer, 82% received long-term VKA (but 17% started after the first week). Among 4,378 patients with cancer, 66% received long term LMWH as monotherapy. In patients without cancer, recent bleeding (odds ratio [OR] 2.70, 95% CI 2.26–3.23), age >70 years (OR 1.15, 95% CI 1.06–1.24), immobility (OR 2.06, 95% CI 1.93–2.19), renal insufficiency (OR 2.42, 95% CI 2.15–2.71) and anemia (OR 1.75, 95% CI 1.65–1.87) predicted poor adherence to guidelines. In those with cancer, anemia (OR 1.83, 95% CI 1.64–2.06), immobility (OR 1.51, 95% CI 1.30–1.76) and metastases (OR 3.22, 95% CI 2.87–3.61) predicted long-term LMWH therapy. In conclusion, we report practices of VTE therapy in real life and found that a significant proportion of patients did not receive the recommended treatment. The perceived increased risk for bleeding has an impact on anticoagulant treatment decision.     

Thoughts about thromboembolic events prophylaxis in cancer patients

The risk of venous thromboembolic events (VTE) in cancer patients is higher than in the general population. Treatment may also increase this risk in these patients. Based on the appropriate criteria (of which the most important are the current ministerial guidelines) thrombosis prophylaxis should be started (given that there is no contraindication) on these patients and be continued while they are at risk. In the event of permanent risk thrombosis prophylaxis should be given lifelong. The drug of choice is low-molecular-weight heparin (LMWH) which is safer and more effective than the oral vitamin K antagonists. Platelet aggregation inhibitors have proved unsuccessful in this patient group. The evidence so far suggests that LMWH (during VTE prophylaxis) can have a positive impact on the course of cancer and perhaps it will be registered under the indication section for cancer patients in the future.     

Venous thromboembolism risk and management in women with cancer and thrombophilia

Background:Venous thromboembolism (VTE) and its complications result in a high rate of morbidity and mortality.Objective:The aim of this study was to review the risk of VTE in women with cancer and other predisposing risk factors, as well as the management of these patients.Methods:Data for this review were identified by searches of MEDLINE, Current Contents, and references from relevant articles using the search terms venous thrombosis, venous thromboembolism, pulmonary embolism, anticoagulation, risk factors, cancer, thrombophilia, heparin, and warfarin. Abstracts and reports from meetings were included only when they directly related to previously published work. Only papers published in English between 1960 and 2005 were included.Results:VTE risk is increased in patients with cancer, with 15% of these patients developing VTE or disseminated intravascular coagulation. Understanding a patient's thromboembolic risk is essential because it affects the type and duration of antithrombotic therapy. The incidence of VTE is dependent on a number of factors, including tumor type, mode of treatment, surgical procedures, patient immobility, and thrombophilia. Progression and recurrence of VTE can be prevented by therapy with unfractionated or low-molecular-weight heparin (LMWH_ followed by warfarin for at least three months. In selected women with advanced cancer disease, a long-term course of LMWH in therapeutic doses is the treatment of choice.Conclusions:In women with cancer, the clinical course is often complicated by VTE episodes. The risk of VTE increases in association with either inherited or acquired thrombophilic conditions. Appropriate management of throemboembolism in women with cancer has the potential to reduce the negative clinical outcomes related to these complications.     

Patterns of Non-Administration of Ordered Doses of Venous Thromboembolism Prophylaxis: Implications for Novel Intervention Strategies

Background

Recent studies have documented high rates of non-administration of ordered venous thromboembolism (VTE) prophylaxis doses. Intervention strategies that target all patients have been effective, but prohibitively resource-intensive. We aimed to identify efficient intervention strategies based on patterns of non-administration of ordered VTE prophylaxis.

Methods and Findings

In this retrospective review of electronic medication administration records, we included adult hospitalized patients who were ordered pharmacologic VTE prophylaxis with unfractionated heparin or enoxaparin over a seven-month period. The primary measure was the proportion of ordered doses of VTE prophylaxis not administered, assessed at the patient, floor, and floor type levels. Differences in non-administration rates between groups were assessed using generalized estimating equations. A total of 103,160 ordered VTE prophylaxis doses during 10,516 patient visits on twenty-nine patient floors were analyzed. Overall, 11.9% of ordered doses were not administered. Approximately 19% of patients missed at least one quarter and 8% of patients missed over one half of ordered doses. There was marked heterogeneity in non-administration rate at the floor level (range: 5–27%). Patients on medicine floors missed a significantly larger proportion (18%) of ordered doses compared to patients on other floor types (8%, Odds Ratio: 2.4, p<0.0001). However, more than half of patients received at least 86% of their ordered doses, even on the lowest performing floor. The 20% of patients who missed at least two ordered doses accounted for 80% of all missed doses.

Conclusions

A substantial proportion of ordered doses of VTE prophylaxis were not administered. The heterogeneity in non-administration rate between patients, floors, and floor types can be used to target interventions. The small proportion of patients that missed multiple ordered doses accounted for a large majority of non-administered doses. This recognition of the Pareto principle provides opportunity to efficiently target a relatively small group of patients for intervention.     

The role of dyslipidemia and statins in venous thromboembolism

Recent studies have proposed an association between hyperlipidemia and venous thromboembolism (VTE). We review the epidemiological evidence linking dyslipidemia with VTE and examine several possible underlying mechanisms. We discuss the possible role of HMG CoA reductase inhibitors (statins) in the prevention and treatment of VTE and suggest future directions for research.